Smith Salley Wealth Management’s Pfizer PFE Stock Holding History

Smith Salley Wealth Management’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-11,929	Closed	-$343K	–	250
2023 Q4	$343K	Sell	11,929 -10,277	-46%	-$311K	0.02%	202
2023 Q3	$736K	Sell	22,206 -1,920	-8%	-$67.9K	0.05%	148
2023 Q2	$885K	Sell	24,126 -1,404	-5%	-$54.6K	0.07%	134
2023 Q1	$1.04M	Buy	25,530 +59	+0.2%	+$2.55K	0.08%	125
2022 Q4	$1.31M	Buy	25,471 +300	+1%	+$14.4K	0.11%	119
2022 Q3	$1.1M	Buy	25,171 +364	+1%	+$17.7K	0.1%	122
2022 Q2	$1.3M	Sell	24,807 -1,021	-4%	-$52K	0.11%	121
2022 Q1	$1.34M	Sell	25,828 -1,126	-4%	-$58.4K	0.1%	124
2021 Q4	$1.59M	Sell	26,954 -282	-1%	-$14K	0.11%	122
2021 Q3	$1.17M	Sell	27,236 -990	-4%	-$43.9K	0.09%	134
2021 Q2	$1.11M	Buy	28,226 +664	+2%	+$25.8K	0.09%	135
2021 Q1	$999K	Sell	27,562 -60,373	-69%	-$2.14M	0.09%	125
2020 Q4	$3.24M	Sell	87,935 -29,011	-25%	-$1.06M	0.33%	69
2020 Q3	$4.07M	Buy	116,946 +185	+0.2%	+$6.49K	0.49%	57
2020 Q2	$3.62M	Buy	116,761 +5,255	+5%	+$179K	0.48%	59
2020 Q1	$3.45M	Sell	111,506 -2,654	-2%	-$90.4K	0.57%	51
2019 Q4	$4.24M	Buy	114,160 +378	+0.3%	+$13.5K	0.56%	56
2019 Q3	$3.88M	Buy	113,782 +5,108	+5%	+$186K	0.55%	59
2019 Q2	$4.47M	Sell	108,674 -5,572	-5%	-$221K	0.67%	49
2019 Q1	$4.6M	Buy	114,246 +1,118	+1%	+$44.8K	0.74%	50
2018 Q4	$4.68M	Sell	113,128 -4,790	-4%	-$199K	0.86%	43
2018 Q3	$4.93M	Sell	117,918 -4,117	-3%	-$158K	0.78%	47
2018 Q2	$4.2M	Sell	122,035 -674	-0.5%	-$23K	0.72%	51
2018 Q1	$4.13M	Buy	122,709 +1,232	+1%	+$42.4K	0.74%	51
2017 Q4	$4.17M	Buy	121,477 +2,494	+2%	+$85K	0.75%	53
2017 Q3	$4.03M	Sell	118,983 -1,669	-1%	-$53.6K	0.77%	51
2017 Q2	$3.85M	Buy	120,652 +1,603	+1%	+$50.6K	0.77%	48
2017 Q1	$3.86M	Buy	119,049 +6,442	+6%	+$203K	0.79%	48
2016 Q4	$3.47M	Buy	112,607 +2,187	+2%	+$66.8K	0.72%	54
2016 Q3	$3.55M	Buy	110,420 +10,315	+10%	+$345K	0.79%	50
2016 Q2	$3.34M	Buy	100,105 +10,737	+12%	+$343K	0.78%	48
2016 Q1	$2.51M	Sell	89,368 -3,178	-3%	-$90.8K	0.63%	54
2015 Q4	$2.83M	Buy	92,546 +446	+0.5%	+$14K	0.71%	48
2015 Q3	$2.74M	Buy	92,100 +1,929	+2%	+$61.9K	0.74%	46
2015 Q2	$2.87M	Buy	90,171 +6,295	+8%	+$205K	0.73%	46
2015 Q1	$2.77M	Buy	83,876 +2,905	+4%	+$92.4K	0.71%	50
2014 Q4	$2.39M	Buy	80,971 +5,224	+7%	+$150K	0.62%	51
2014 Q3	$2.13M	Sell	75,747 -631	-0.8%	-$17.7K	0.56%	57
2014 Q2	$2.15M	Buy	76,378 +54,129	+243%	+$1.54M	0.57%	63
2014 Q1	$678K	Sell	22,249 -77,039	-78%	-$2.3M	0.42%	60
2013 Q4	$2.88M	Buy	99,288 +8,268	+9%	+$241K	1.88%	20
2013 Q3	$2.48M	Buy	91,020 +2,838	+3%	+$77.2K	2%	22
2013 Q2	$2.34M	Buy	+88,182	New	+$2.44M	1.88%	23

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

Smith Salley Wealth Management's PFE Position: Q1 2024 in Review

Smith Salley Wealth Management sold out of Pfizer (PFE) in Q1 2024, closing a stake of 11,929 shares — an estimated $343K sold.

Smith Salley Wealth Management first reported a position in PFE in Q2 2013 and held it in 43 quarters. The position peaked at $4.93M in Q3 2018. 2,874 funds tracked by Wall St. Rank hold PFE as of Q1 2024.

Smith Salley Wealth Management reported no remaining Pfizer position as of Q1 2024 after selling out during the quarter.
Smith Salley Wealth Management sold 11,929 Pfizer shares in Q1 2024, an estimated $343K.
Smith Salley Wealth Management first reported a position in Pfizer in Q2 2013 and held it in 43 quarters.
Smith Salley Wealth Management's Pfizer position peaked at $4.93M in Q3 2018.
2,874 funds tracked by Wall St. Rank held Pfizer as of Q1 2024.

Based on Smith Salley Wealth Management's 13F filing for Q1 2024, filed 2 May 2024.